Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Leukemia & Lymphoma Society (LLS) and Forma Therapeutics have entered into a partnership to discover and develop novel therapies for cancer patients with diffuse large B cell lymphoma. The companies aim to develop small molecule compounds against the key lymphoma target, Bcl-6.
Subscribe to our email newsletter
LLS has committed substantial, multi-year funding to support this collaboration, which is an expansion of partnership between both the companies in July 2009, as part of its Therapy Acceleration Program (TAP).
TAP is designed to advance therapies with high prospects of providing near-term benefit to patients suffering from blood cancers, LLS said.
B lymphocyte cells, which are important component of the body’s immune system, can become cancerous, leading to diseases such as non-Hodgkin’s lymphoma. Bcl-6 is a transcriptional repressor that down-regulates hundreds of genes important for control of function of normal and tumor cells.
LLS said that the project focuses on blocking Bcl-6 interaction with a protein co-repressor called SMRT.
John Walter, CEO of LLS, said: “Together LLS and Forma hope to change the standard of care and improve the quality of life for patients suffering from blood cancer.”
Steven Tregay, CEO of Forma, said: “Our highly skilled team is dedicated to sharing our industry knowledge with LLS, leveraging our unique Computational Solvent (CS) Mapping technology to aid in structure-based drug design, screening and medicinal chemistry competence.”